RT Journal Article
T1 Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.
A1 Obón-Santacana, Mireia
A1 Lujan-Barroso, Leila
A1 Travis, Ruth C
A1 Freisling, Heinz
A1 Ferrari, Pietro
A1 Severi, Gianluca
A1 Baglietto, Laura
A1 Boutron-Ruault, Marie-Christine
A1 Fortner, Renée T
A1 Ose, Jennifer
A1 Boeing, Heiner
A1 Menéndez, Virginia
A1 Sánchez-Cantalejo, Emilio
A1 Chamosa, Saioa
A1 Castaño, José María Huerta
A1 Ardanaz, Eva
A1 Khaw, Kay-Tee
A1 Wareham, Nick
A1 Merritt, Melissa A
A1 Gunter, Marc J
A1 Trichopoulou, Antonia
A1 Papatesta, Eleni-Maria
A1 Klinaki, Eleni
A1 Saieva, Calogero
A1 Tagliabue, Giovanna
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Mattiello, Amalia
A1 Bueno-de-Mesquita, H B
A1 Peeters, Petra H
A1 Onland-Moret, N Charlotte
A1 Idahl, Annika
A1 Lundin, Eva
A1 Weiderpass, Elisabete
A1 Vesper, Hubert W
A1 Riboli, Elio
A1 Duell, Eric J
AB Acrylamide was classified as "probably carcinogenic to humans (group 2A)" by the International Agency for Research on Cancer. Epithelial ovarian cancer (EOC) is the fourth cause of cancer mortality in women. Five epidemiological studies have evaluated the association between EOC risk and dietary acrylamide intake assessed using food frequency questionnaires, and one nested case-control study evaluated hemoglobin adducts of acrylamide (HbAA) and its metabolite glycidamide (HbGA) and EOC risk; the results of these studies were inconsistent. A nested case-control study in nonsmoking postmenopausal women (334 cases, 417 controls) was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Unconditional logistic regression models were used to estimate ORs and 95% confidence intervals (CI) for the association between HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA and EOC and invasive serous EOC risk. No overall associations were observed between biomarkers of acrylamide exposure analyzed in quintiles and EOC risk; however, positive associations were observed between some middle quintiles of HbGA and HbAA+HbGA. Elevated but nonstatistically significant ORs for serous EOC were observed for HbGA and HbAA+HbGA (ORQ5vsQ1, 1.91; 95% CI, 0.96-3.81 and ORQ5vsQ1, 1.90; 95% CI, 0.94-3.83, respectively); however, no linear dose-response trends were observed. This EPIC nested case-control study failed to observe a clear association between biomarkers of acrylamide exposure and the risk of EOC or invasive serous EOC. It is unlikely that dietary acrylamide exposure increases ovarian cancer risk; however, additional studies with larger sample size should be performed to exclude any possible association with EOC risk.
YR 2015
FD 2015-11-23
LK http://hdl.handle.net/10668/9630
UL http://hdl.handle.net/10668/9630
LA en
DS RISalud
RD Apr 6, 2025